MRI demonstration of gadolinium deposition in bone after monthly triple-dose gadopentetate dimeglumine and correlation with frequency of hypophosphatemia.

[1]  M. Crook,et al.  Disorders of phosphate metabolism , 2019, Journal of Clinical Pathology.

[2]  M. Bobinski,et al.  Gadolinium Deposition within the Pediatric Brain: No Increased Intrinsic T1-Weighted Signal Intensity within the Dentate Nucleus following the Administration of a Minimum of 4 Doses of the Macrocyclic Agent Gadoteridol , 2018, American Journal of Neuroradiology.

[3]  F. McNeill,et al.  Observed Deposition of Gadolinium in Bone Using a New Noninvasive in Vivo Biomedical Device: Results of a Small Pilot Feasibility Study. , 2017, Radiology.

[4]  H. Jara,et al.  Global and Regional Brain Assessment with Quantitative MR Imaging in Patients with Prior Exposure to Linear Gadolinium-based Contrast Agents. , 2017, Radiology.

[5]  M. Bellomi,et al.  Signal intensity change on unenhanced T1-weighted images in dentate nucleus and globus pallidus after multiple administrations of gadoxetate disodium: an intraindividual comparative study , 2017, European Radiology.

[6]  Martin R Prince,et al.  Extent of Signal Hyperintensity on Unenhanced T1-weighted Brain MR Images after More than 35 Administrations of Linear Gadolinium-based Contrast Agents. , 2017, Radiology.

[7]  D. Hippe,et al.  Macrocyclic and Other Non–Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function , 2016, Investigative radiology.

[8]  Pascal J. Kieslich,et al.  Increased Signal Intensity in the Dentate Nucleus on Unenhanced T1-Weighted Images After Gadobenate Dimeglumine Administration , 2015, Investigative radiology.

[9]  S. Cook,et al.  Hypophosphatemia is Associated with the Serial Administration of Triple‐Dose Gadolinium to Patients for Brain MRI , 2015, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[10]  Vincenzo Di Lazzaro,et al.  Progressive Increase of T1 Signal Intensity of the Dentate Nucleus on Unenhanced Magnetic Resonance Images Is Associated With Cumulative Doses of Intravenously Administered Gadodiamide in Patients With Normal Renal Function, Suggesting Dechelation , 2014, Investigative radiology.

[11]  Daisuke Takenaka,et al.  High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. , 2014, Radiology.

[12]  Peter Caravan,et al.  Primer on gadolinium chemistry , 2009, Journal of magnetic resonance imaging : JMRI.

[13]  J. Skurnick,et al.  Effect of anti-IFNβ antibodies on MRI lesions of MS patients in the BECOME study , 2009, Neurology.

[14]  P. Hauschka,et al.  Incorporation of excess gadolinium into human bone from medical contrast agents. , 2009, Metallomics : integrated biometal science.

[15]  J. Skurnick,et al.  Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study , 2009 .

[16]  Michael Uder,et al.  Cytotoxicity of iodinated and gadolinium-based contrast agents in renal tubular cells at angiographic concentrations: in vitro study. , 2007, Radiology.

[17]  M. Tweedle,et al.  Comparison of Gd(DTPA-BMA) (Omniscan) Versus Gd(HP-DO3A) (ProHance) Relative to Gadolinium Retention in Human Bone Tissue by Inductively Coupled Plasma Mass Spectroscopy , 2006, Investigative radiology.

[18]  Jiang Liu,et al.  Safety of Serial Monthly Administration of Triple‐Dose Gadopentetate Dimeglumine in Multiple Sclerosis Patients: Preliminary Results of the BECOME Trial , 2005, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[19]  M. Ronjat,et al.  Effect of gadolinium on the ryanodine receptor/sarcoplasmic reticulum calcium release channel of skeletal muscle , 2005, The FEBS journal.

[20]  A. Blumsohn.  What have we learnt about the regulation of phosphate metabolism? , 2004, Current opinion in nephrology and hypertension.

[21]  W. Gibby,et al.  Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) Retention in Human Bone Tissue by Inductively Coupled Plasma Atomic Emission Spectroscopy , 2004, Investigative radiology.

[22]  J Sykes,et al.  An investigation of the toxicity of gadolinium based MRI contrast agents using neutron activation analysis. , 2003, Magnetic resonance imaging.

[23]  H. Murer,et al.  Molecular aspects in the regulation of renal inorganic phosphate reabsorption: the type IIa sodium/inorganic phosphate co-transporter as the key player , 2001, Current opinion in nephrology and hypertension.

[24]  J. Hajnal,et al.  Reduction of CSF and blood flow artifacts on FLAIR images of the brain with k-space reordered by inversion time at each slice position (KRISP). , 2001, AJNR. American journal of neuroradiology.

[25]  S. Cook,et al.  Triple‐Dose Versus Single‐Dose Gadoteridol in Multiple Sclerosis Patients , 1994, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[26]  J. Foreman,et al.  The Fanconi syndrome and mechanisms of tubular transport dysfunction. , 1981, Kidney international.

[27]  A. Carlsson.  The cause of hypophosphatemia and hypocalcemia in vitamin D deficiency. , 1954, Acta physiologica Scandinavica.

[28]  U. Karst,et al.  LA-ICP-MS/MS improves limits of detection in elemental bioimaging of gadolinium deposition originating from MRI contrast agents in skin and brain tissues. , 2019, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

[29]  A. Yu,et al.  Disorders of Calcium, Magnesium, and Phosphate Balance , 2012 .

[30]  A. Dusso,et al.  Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.